Optiver Holding
TRDA icon

Optiver Holding’s Entrada Therapeutics TRDA Stock Holding History

Optiver Holding’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.26K Sell
258
-88
-25% -$1.01K ﹤0.01% 1619
2025
Q4 		$3.56K Hold
346
– – ﹤0.01% 1628
2025
Q3 		$2.01K Buy
+346
New +$2.02K ﹤0.01% 2385

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Optiver Holding's TRDA Position: Q1 2026 in Review

Optiver Holding reduced its Entrada Therapeutics (TRDA) stake by 25% in Q1 2026, selling an estimated $1.01K and leaving 258 shares worth $3.26K. The position accounts for ﹤0.01% of the portfolio, ranked #1619.

Optiver Holding first reported a position in TRDA in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.56K in Q4 2025. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Optiver Holding held 258 shares of Entrada Therapeutics worth $3.26K as of Q1 2026.
  • Optiver Holding sold 88 Entrada Therapeutics shares in Q1 2026, an estimated $1.01K.
  • Entrada Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1619 holding.
  • Optiver Holding first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Entrada Therapeutics position peaked at $3.56K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.